MAIA Biotechnology (MAIA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
7 Apr, 2026Voting matters and shareholder proposals
Election of Class I Directors, with nominees Louie Ngar Yee and Steven Chaouki recommended for election by the board.
Ratification of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Additional business may be considered if properly brought before the meeting or any adjournment.
Board of directors and corporate governance
Board recommends the election of two Class I Director nominees at the annual meeting.
Audit committee and external auditor matters
Grant Thornton LLP proposed for ratification as the external auditor for the 2026 fiscal year.
Partial view of Summaries dataset, powered by Quartr API
Latest events from MAIA Biotechnology
- $33M equity raise boosts cash to $34.4M, funding Phase 3 NSCLC trial; net loss rises to $6.37M.MAIA
Q1 202611 May 2026 - Proxy statement amended to disclose equity compensation plan details and available shares.MAIA
Proxy filing27 Apr 2026 - Virtual meeting to elect directors and ratify auditor, with strong governance and director alignment.MAIA
Proxy filing7 Apr 2026 - Advanced clinical pipeline and $33M capital raise position company for pivotal 2026 milestones.MAIA
Q4 202523 Mar 2026 - THIO's pivotal trials show high efficacy in cancer, with major milestones and approvals expected by 2026.MAIA
Biotech Showcase 2025 Investor Conference10 Jan 2026 - Key votes include director elections, auditor ratification, and a major share authorization increase.MAIA
Proxy Filing2 Dec 2025 - Shareholders will vote on director elections, auditor ratification, and doubling authorized shares.MAIA
Proxy Filing2 Dec 2025 - Shareholders to vote on director elections, auditor ratification, and doubling authorized common stock.MAIA
Proxy Filing2 Dec 2025 - Q3 2025 saw higher losses, key clinical progress, and a shift toward digital asset treasury.MAIA
Q3 20257 Nov 2025